2',4'-dimethyl-3-(4-methoxyphenyl)propiophenone, 97.0%, 1g

4-((3,4-DIMETHYLPHENYL)AMINO)-7-(PYRIDIN-4-YL)QUINOLINE-3-CARBOXAMIDE, 95%, 50mg

Ethyl 3-oxopiperidine-4-carboxylate hydrochloride, 95.0%, 5g

N-(4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)acetamide, 95.0%, 250mg

[S(R)]-N-[(S)-[3,5-Di-tert-butyl-4-methoxyphenyl][(3-benzyloxy-2-(dicyclohexylphosphino)phenyl)methyl]-2-methyl-2-propanesulfinamide, 95%, 5mg

Alcool benzylique, min 98 %, pour la synthèse, 2,5 L, emballage en verre

((2-Fluoro-6-(methoxymethoxy)-8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)naphthalen-1-yl)ethynyl)triisopropylsilane, 97%, 1g

tert-Butyl 1,6-diazaspiro[3.3]heptane-6-carboxylate oxalate(2:1), 97%, 100mg

2-(3-aminopiperidin-1-yl)ethan-1-ol dihydrochloride, 96%, 100mg

2-amino-5-methyl-1,3-thiazol-4(5H)-one, 95%, 10g

Methyl 4-ethynyl-2-hydroxybenzoate, 98%, 1g

5-Bromo-6-chloro-1H-indazole, 95.0%, 250mg

2-Bromo-N-(3,5-dichlorophenyl)acetamide, 95+%, 100mg